Atopic Dermatitis CD56+ NK Cells
Atopic Dermatitis CD56+ NK Cells come from IRB-consented donors with atopic dermatitis. Relevant for exploring NK cell involvement in Th2-skewed inflammation, barrier dysfunction, and altered cytolytic activity in chronic eczema.
Atopic Dermatitis CD56+ NK Cells for Allergy and Inflammation Research
Atopic Dermatitis CD56+ NK Cells are cryopreserved from peripheral blood of IRB-consented adult donors diagnosed with atopic dermatitis. These CD56+ CD3− natural killer cells reflect disease-associated innate immune alterations and support studies of immune surveillance, Th2-skewed inflammation, and cytotoxicity.
NK Cells in Atopic Dermatitis
Atopic dermatitis is a chronic, relapsing inflammatory skin disease driven by epidermal barrier dysfunction and type 2 (Th2) immune skewing — not by autoimmunity. The IL-4/IL-13 axis underlies the current generation of biologics, and NK cells are increasingly recognised as participants rather than bystanders:
- Reduced circulating NK cell numbers and impaired cytotoxicity, reported consistently in moderate-to-severe disease
- Type 2 cytokine skewing — a subset of NK cells produces IL-5 and IL-13, contributing directly to the Th2 milieu rather than counterbalancing it
- Proposed regulatory role — reduced NK function has been linked to failure to restrain type 2 inflammation, making NK deficiency a candidate mechanism rather than an epiphenomenon
- Susceptibility to cutaneous viral infection — impaired NK surveillance is one proposed contributor to eczema herpeticum and increased S. aureus colonisation
- Treatment effects — dupilumab and JAK inhibitors measurably shift the innate compartment, so treatment status is essential context
Donor Stratification Available
- Disease severity — EASI, SCORAD, or IGA scores where recorded
- Total and allergen-specific IgE where tested
- Atopic comorbidities — asthma, allergic rhinitis, food allergy
- Treatment status — topical-only, or on dupilumab, JAK inhibitor, or systemic immunosuppressant
- Flare status — active flare vs quiescent disease
- Matched healthy controls available
Product Features
- Research Use Only (RUO), CD56+ enriched NK cells
- Isolated from clinically diagnosed atopic dermatitis donors
- High viability and enrichment
- Cryopreserved in CryoStor® CS10 media
- Processed within 24 hours of collection
- Flow cytometry purity and viability data per lot
- Ethically sourced with IRB approval and HIPAA compliance
De-identified Donor Data
- Confirmed diagnosis of atopic dermatitis
- Demographics: age, sex assigned at birth, race/ethnicity
- Self-reported clinical history and medication use
Applications
- NK cell phenotype and function studies in atopic dermatitis
- Type 2 inflammation and IL-4/IL-13 axis research
- Cytotoxicity, degranulation, and CD56-bright/dim subset analysis
- Biologic and JAK inhibitor mechanism-of-action research
- Cutaneous antiviral and antibacterial surveillance studies
- Single-cell analysis and biomarker identification
- Preclinical immunotherapy development
Other Atopic Dermatitis Specimen Types
Matched material from atopic dermatitis donors is available as AD CD19+ B cells, PBMC, serum, plasma, and skin punch biopsy for lesional tissue. Related atopic cohorts include allergy serum and chronic spontaneous urticaria.
Compliance and Quality Assurance
- IRB-approved collection and 21 CFR Part 11-compliant e-consent
- Standardized processing and quality protocols
- HIPAA-compliant data handling
Ordering & Customization
Atopic Dermatitis CD56+ NK Cells are offered in standard or custom aliquot sizes. For pricing, regulatory documentation, or international support, contact learnmore@sanguinebio.com. For the full range, see our human CD56+ NK cells collection.
Protocols & Documentation
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom CD56+ NK Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.